Skip to Content

Join the 'Optivate' group to help and get support from people like you.

Optivate News

Kids' Hemophilia Drugs a Big Part of State Medicaid Spending

Posted 31 Jul 2015 by

FRIDAY, July 31, 2015 – Treatment costs for one childhood illness, hemophilia, may use up a big chunk of a state's Medicaid budget, a new study out of California shows. The researchers found that treatments for hemophilia – a rare, inherited disorder in which blood does not clot normally – accounted for the largest share of spending on outpatient drugs among publicly insured children in California with serious chronic illnesses. The study "underscores the potential effect of new, expensive but [effective] pharmaceuticals on public insurance programs for children with chronic illness," wrote a group led by Sonja Swenson of Stanford University. Her team published the findings July 28 in the Journal of the American Medical Association. The researchers tracked 2010-2012 data from more than 34,300 publicly insured children and young adults under the age of 21 in California with serious ... Read more

Related support groups: Hemophilia A, Hemophilia, Antihemophilic Factor, Hemophilia B, ReFacto, Humate-P, Advate, Recombinate, Helixate FS, Antihemophilic Factor/Von Willebrand Factor, Bioclate, Kogenate FS, Replenate, Hemofil-M, Liberate, Factane, Xyntha, Hyate:C, Monoclate, Eloctate

Ask a Question

Further Information

Related Condition Support Groups

Hemophilia A, von Willebrand's Disease

Optivate Patient Information at